Annexon, Inc. Common Stock
ANNX
ANNX: Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases.
moreShow ANNX Financials
Recent trades of ANNX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ANNX's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Anti-complement factor c1q antibodies and uses thereof May. 16, 2023
-
Patent Title: Anti-complement factor c1q antibodies and uses thereof Feb. 23, 2021
-
Patent Title: Anti-complement factor c1q fab fragments and uses thereof Jul. 28, 2020
-
Patent Title: Anti-complement factor c1q antibodies and uses thereof Mar. 17, 2020
-
Patent Title: Humanized anti-complement factor c1q antibodies Jun. 11, 2019
-
Patent Title: Anti-complement factor c1q antibodies and uses thereof Mar. 12, 2019
-
Patent Title: Anti-complement factor c1q antibodies and uses thereof Jul. 18, 2017
Federal grants, loans, and purchases
Followers on ANNX's company Twitter account
Number of mentions of ANNX in WallStreetBets Daily Discussion
Recent insights relating to ANNX
Recent picks made for ANNX stock on CNBC
ETFs with the largest estimated holdings in ANNX
Flights by private jets registered to ANNX